Comment: J&J, Synthes merger likely to attract scrutiny in trauma products sector
US healthcare group Johnson & Johnson's 14 billion euro purchase of Swiss medical device maker Synthes is expected to draw regulatory scrutiny of the companies' combined offerings in products used for the...To view the full article, register now.
Already a subscriber? Click here to view full article